

DI
cont

5. (Twice Amended) A composition for the treatment of glaucoma and ocular hypertension comprising a therapeutically active and physiologically acceptable amount of a prostaglandin analogue which is a selective agonist for EP₁ prostanoid receptors, or a pharmaceutically acceptable salt or ester thereof, wherein the prostaglandin analogue is 13,14-dihydro-17-(3-fluorophenyl)-18,19,20-trinor-PGE₂ or an alkyl ester thereof.

18. (Amended) The method according to claim 8, wherein R is C₁₋₁₀ alkyl, C₃₋₈ cycloalkyl or aryl-C₂₋₅ alkyl.

19. (Amended) The method according to claim 8, wherein R₁ is C₃₋₇ cycloalkyl or C₃₋₇ cycloalkenyl.

C2

20. (Amended) The method according to claim 8, wherein R₂ is hydrogen, hydroxy, methyl, ethyl, methoxy or OCOR₄, wherein R₄ is C₁₋₁₀ alkyl or C₃₋₈ cycloalkyl.

21. (Amended) The method according to claim 8, wherein R₃ is a straight or branched chain saturated or unsaturated alkyl group having 3-8 carbon atoms, optionally interrupted by one or more heteroatoms selected from the group consisting of oxygen, sulfur and nitrogen, each carbon atom optionally substituted with a substituent selected from C₁₋₅ alky, hydroxy and carbonyl groups, wherein the hydroxy and carbonyl are attached to carbon 15 of the prostaglandin structure, and said alkyl group optionally containing a C₃₋₈ cycloalkyl, optionally mono- or independently tri-substituted with C₁₋₃ alkyl, C₁₋₃ alkoxy, hydroxy, nitro, trifluoromethyl or halogen.
